OpenAI acquires Orchestra Bio to expand life sciences AI

OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that last raised $20 million in venture funding. Orchestra develops AI agents to streamline drug discovery workflows, such as monitoring compound manufacturing and tracking trials, rather than exploring new compounds. The team will work on GPT Rosalind, OpenAI's life sciences model variant, which was released as a full commercial product alongside Rosalind Workbench, a suite of agents for connecting to scientific instruments. OpenAI stated its vision is to help scientists across the full medicine development process, emphasizing collaboration with partners like Novo Nordisk and Moderna to accelerate R&D.

This move distinguishes OpenAI's strategy from Anthropic's, which involves operating its own wet lab. OpenAI focuses on building tools for existing pharmaceutical industries rather than internalizing scientific results. By acquiring Orchestra Bio, OpenAI is positioning itself as a tool provider for the existing pharma industry, aiming to accelerate R&D through better AI infrastructure. The acquisition underscores a strategic shift toward serving established scientific workflows rather than competing directly as a biotech firm. OpenAI's approach aims to leverage AI to optimize the efficiency of drug development pipelines, potentially reducing costs and time-to-market for partner pharmaceutical companies.